Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

<strong>Background<br></strong> Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia. Addition of amodiaquine to artemether–lumefantrine could provide an efficacious trea...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Peto, TJ, Tripura, R, Callery, JJ, Lek, D, Nghia, HDT, Nguon, C, Thuong, NTH, van der Pluijm, RW, Dung, NTP, Sokha, M, Luong, VV, Long, LT, Sovann, Y, Duanguppama, J, Waithira, N, Hoglund, RM, Chotsiri, P, Chau, NH, Ruecker, A, Amaratunga, C, Dhorda, M, Miotto, O, Maude, RJ, Rekol, H, Chotivanich, K, Tarning, J, von Seidlein, L, Imwong, M, Mukaka, M, Day, NPJ, Hien, TT, White, NJ, Dondorp, AM
Formaat: Journal article
Taal:English
Gepubliceerd in: Elsevier 2022

Gelijkaardige items